| Name | Title | Contact Details |
|---|---|---|
Jacqui Boire |
Director, Technology Strategy and Planning | Profile |
Melior Discovery Inc (Exton, PA, USA) has pioneered a unique high throughput in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. theraTRACE® is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates. Melior has also leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.
Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.
Vision Innovation Partners unites the mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of a leading middle-market private equity firm.
Sunovion Pharmaceuticals Inc., known until October 12, 2010 as Sepracor, Inc.